US10485841B2ActiveUtilityA1
Method for producing dry extracts
Est. expiryAug 19, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Michael A. Popp
A61P 31/12A61P 31/04A61P 31/00A61P 29/00A61P 27/16A61P 3/02A61P 17/02A61P 17/00A61P 11/12A61P 11/04A61P 11/02A61P 11/00A61P 1/02A61K 36/515A61K 2236/333A61K 36/35A61K 36/70A23V 2002/00A61K 2236/331A61K 36/85A61K 2236/53A61K 2236/33A23L 33/105A61K 2236/51A61K 2300/00A61K 36/185
56
PatentIndex Score
0
Cited by
26
References
20
Claims
Abstract
The invention relates to a method for producing dry extracts of plants and to pharmaceutical preparations containing the same, more particularly phytopharmaceuticals, which contain at least one ethanolic/aqueous extract of a plant (drug), the plants being selected from the group consisting of: Rumicis herba; Verbena officinalis; Sambucus nigra; Primula veris; and Gentiana lutea and mixtures thereof. The invention further relates to a pharmaceutical for treating inflammatory and/or infectious diseases of the nose and throat area and/or the nasal sinuses, as well as the use thereof.
Claims
exact text as granted — not AI-modifiedI claim:
1. A composition for treating sinusitis, rhinosinusitis or inflammation of the nasal sinuses in a human in need thereof consisting essentially of a therapeutically effective amount of a dry plant extract mixture wherein said dry plant extract mixture is obtained by a method consisting essentially of:
a) obtaining a first extraction of Rumicis herba, Verbena officinalis, Sambucus nigra, Primula veris and Gentiana lutea with water and alcohol to produce a first supernatant;
b) separating the first supernatant to form a residue;
c) extracting the residue with water to form a second aqueous extraction to form obtain a second supernatant;
d) separating the second supernatant from the aqueous extractant;
e) combining the first supernatant and the second supernatant; and
f) drying the first and second supernatants to form the dry plant mixture which effectively treats the sinusitis, rhinosinusitis or inflammation of the nasal sinuses in a human in need thereof.
2. The composition of claim 1 , wherein the ratio of Gentiana lutea :Rumicis herba: Verbena officinalis:Sambucus nigra:Primula veris in step a) is 1:3:3:3:3.
3. The composition of claim 1 , wherein the water/alcohol extraction agent in step a) has a content of 40:60 (v/v) to 60:40 (v/v) water/alcohol.
4. The composition of claim 1 , wherein the water/alcohol extraction agent in step a) a content of 41:59 (v/v) water/alcohol.
5. The composition of claim 1 , wherein the water/alcohol extraction agent in step a) has a content of 50:50 (v/v) water/alcohol.
6. The composition of claim 1 , wherein the water/alcohol extraction agent in step a) is ethanol and water.
7. The composition of claim 1 , wherein the water/alcohol extraction agent in step a) is 96% ethanol.
8. The composition of claim 1 , wherein the plants in step a) are provided together in a batch.
9. The composition of claim 1 , wherein the extraction in steps a) and c) is carried out at 20 to 40° C.
10. The composition of claim 1 , wherein the extraction in steps a) and c) is carried out in 2 to 8 hours.
11. The composition of claim 1 , wherein the drying process of step e) is carried out under vacuum at 30 to 60° C.
12. The composition of claim 1 , wherein the drying process of step e) is carried out under vacuum at 40 to 50° C.
13. The composition of claim 1 , wherein the drying process of step e) is carried out in a vacuum agitated dryer.
14. The composition of claim 1 for use as an antibacterial, antiviral or anti-inflammatory agent.
15. A method for treating sinusitis, rhinosinusitis, inflammation of the nasal sinuses, or treating a disease of the entire respiratory tract of a human in need thereof consisting essentially of administering the composition of claim 1 in to the human in need thereof.
16. The method of claim 15 , wherein the sinusitis, rhinosinusitis, or inflammation of the nasal sinuses is in acute form.
17. The method of claim 15 , wherein the sinusitis, rhinosinusitis, or inflammation of the nasal sinuses is caused by a disease of the entire respiratory tract.
18. The method of claim 16 , wherein the disease of the entire respiratory tract is a disease of the upper airways.
19. The method of claim 16 , wherein the disease of the entire respiratory tract is a disease in the region of throat, nose and nasal sinus mucous membranes.
20. The method of claim 16 , wherein the disease of the entire respiratory tract is cystic fibrosis.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.